Mannan-binding lectin serine protease 2 · SINGLE PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14Mannan-binding lectin serine protease 2 shows late clinical disease relevance led by atypical hemolytic-uremic syndrome. 3 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt O00187. Start with atypical hemolytic-uremic syndrome, then reuse UniProt O00187 as the stable protein anchor across project notes and exports.
Start with atypical hemolytic-uremic syndrome, then reuse UniProt O00187 as the stable protein anchor across project notes and exports.
Mannan-binding lectin serine protease 2 shows late clinical disease relevance led by atypical hemolytic-uremic syndrome. 3 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with atypical hemolytic-uremic syndrome because it currently carries late clinical support. Linked drugs include NARSOPLIMAB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyMannan-binding lectin serine protease 2
Review this target as Mannan-binding lectin serine protease 2, mapped to UniProt O00187. Sequence length is 686 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Mannan-binding lectin serine protease 2 as ChEMBL target CHEMBL4295646, mapped to UniProt O00187. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Mannan-binding lectin serine protease 2 is the right protein anchor across sources, using UniProt O00187 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why atypical hemolytic-uremic syndrome is currently framed as late clinical support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Mannan-binding lectin serine protease 2 |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | O00187 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Mannan-binding lectin serine protease 2 |
| UniProt Accession | O00187 |
| Component Type | Protein |
| Sequence Length | 686 aa |
Mannan-binding lectin serine protease 2
Review this target as Mannan-binding lectin serine protease 2, mapped to UniProt O00187. Sequence length is 686 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Mannan-binding lectin serine protease 2 shows late clinical disease relevance led by atypical hemolytic-uremic syndrome. 3 more disease programs remain visible in the same review block.
Start review with atypical hemolytic-uremic syndrome because it currently carries late clinical support. Linked drugs include NARSOPLIMAB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL4242955 | 8.22 | Ki | 6.0 | Preclinical |
| CHEMBL4242955 | 7.18 | IC50 | 66.0 | Preclinical |
| CHEMBL4246684 | 6.75 | Ki | 180.0 | Preclinical |
| CHEMBL4240381 | 6.64 | IC50 | 230.0 | Preclinical |
| CHEMBL4242095 | 6.36 | Ki | 440.0 | Preclinical |
| CHEMBL4240381 | 5.99 | Ki | 1030.0 | Preclinical |
| CHEMBL5751330 | 5.82 | Ki | 1500.0 | Preclinical |
| CHEMBL5761304 | 5.82 | Ki | 1500.0 | Preclinical |
| CHEMBL5762749 | 5.82 | Ki | 1500.0 | Preclinical |
| CHEMBL5768713 | 5.82 | Ki | 1500.0 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 6 | 169 | 5.3 |
| cell-based format | 2 | 1 | 6.4 |